This case report is part of an ongoing phase I clinical trial (NCT02122861, Table 1) investigating the use of intradermal NY-ESO-1-specific lentiviral DC-targeting in melanoma, non-small cell lung cancer, ovarian cancer, and sarcoma. This evidence concerns the gene CTAG1B and ovarian carcinoma.